Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Université Paul Sabatier (toulouse Iii)

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Ecole Nationale Superieure De Chimie De Montpellier

Centre Hospitalier Universitaire De Toulouse

Ecole Nationale Veterinaire De Toulouse

Centre National De La Recherche Scientifique-cnrs

Inserm (institut National De La Sante Et De La Recherche Medicale)

Justine Bertrand-Michel

Thierry Durand

Eric Oswald

Patricia Martin

Nicolas Cenac

Alexandre Guy

Teresa Perez-Berezo

Pauline Le Faouder

Julien Pujo

Jean-Marie Galano

The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probioticstrain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Lipopeptide compounds for the treatment of pain disorders

Growing community of inventors

Toulouse, France

Justine Bertrand-Michel